Serum Levels of OX40 in Early and Late-Stage Oral Squamous Cell Carcinoma
| Autor: | Syed Zaryab Ahmed, Mervyn Hosein, Aliya Irshad Sani, Moazzam Ali Shahid, Shumaila Usman, Zil E Rubab |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Disease 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine cancer Basal cell In patient business.industry General Engineering Late stage ox40 Cancer Immunotherapy Buccal administration immune checkpoints medicine.disease oral squamous cell carcinoma stomatognathic diseases Oncology Tumor necrosis factor alpha Other immunotherapy business 030217 neurology & neurosurgery |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.14597 |
| Popis: | Background The tumor necrosis factor receptor superfamily, member 4 (OX40) and its ligand (OX40L) are members of the tumor necrosis factor superfamily and play roles as costimulatory immunomodulators to combat infectious diseases as well as cancers. Presently, many therapeutic agents focused on OX40 and OX40L are in trials for antitumor efficacy. In Pakistan, oral squamous cell carcinoma (OSCC) is the second most prevalent cancer with a mortality of 50% despite the availability of various therapeutic modalities. Data regarding serum levels of OX40 in patients with OSCC is lacking. Therefore, the study aimed to assess the OX40 levels in serum and their association with the clinicopathological features of the tumor. Methodology A cross-sectional study was conducted and serum samples of 78 biopsy-confirmed OSCC patients were collected prior to any treatment along with 10 healthy persons after informed consent. Serum levels of OX40 were measured via sandwich enzyme-linked immunosorbent assay (ELISA). Results The mean serum levels of OX40 were 1.65 ± 0.64 ng/ml and 2.39 ± 0.58 ng/ml in early and late-stage disease patients of OSCC, respectively (p = |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|